Back to Hepatology
Hepatologyv2003Evidence-Based

AST to Platelet Ratio Index (APRI)

Determines the likelihood of hepatic fibrosis and cirrhosis in patients with hepatitis C using readily available laboratory values.

Clinical Input Parameters

U/L
Range: 1 — 2000 U/L
U/L
Range: 10 — 100 U/L
× 10³/µL
Range: 10 — 1000 × 10³/µL
Clinical Assessment
Awaiting Parameters
apri score
—index
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The AST to Platelet Ratio Index (APRI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hepatology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

APRI = [(AST/AST upper limit of normal) × 100] / Platelet count (×10³/µL)

Clinical Pearls & Practice Notes

  • Originally developed and validated in hepatitis C patients
  • APRI has better negative predictive value than positive predictive value
  • Low APRI scores are reliable for ruling out cirrhosis, but APRI is less sensitive for identifying cirrhosis
  • Consider using in combination with other non-invasive markers for improved accuracy
  • May be less accurate in patients with acute hepatitis, portal hypertension, or other causes of thrombocytopenia
  • The AST upper limit of normal may vary by laboratory (commonly 40 U/L for males, 32 U/L for females)

Evidence & Literature Citations

  1. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.
  2. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46(3):912-21.
  3. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726-36.

Score Interpretation Ranges

Low Risk0 – 0.3 pts

Rules out significant fibrosis

Low-Intermediate Risk0.3 – 0.5 pts

Low probability of cirrhosis

Intermediate Risk0.5 – 1.5 pts

Indeterminate risk

High Risk1.5 – 2 pts

Suggests significant fibrosis

Very High Risk2 – 100 pts

Suggests cirrhosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.